
    
      It is an open random prospective phase III clinical trial conducted by Principal Investigator
      Professor Zhi-ping Yan.Investigators in twenty-seven hospitals in China participate
      in.Patients with unresectable HCC with main portal vein tumor thrombus are enrolled. The
      investigators propose to recruitment 253 patients who are randomly assigned into the combined
      group (treated with endovascular brachytherapy combined with stent placement and TACE) and
      the control group (treated with TACE alone).There are 127 patients in combined group and 126
      patients in control group. The criteria of inclusion and exclusion, and the methods of lab
      tests, imaging modality and treatment procedures are the same.
    
  